“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

05 July 2019
Pharma

Visiongain has launched a new pharma report Global Influenza Vaccines Market Report : Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other.

Growth is mainly driven by the ageing population and the increasing prevalence of health problems associated with age. This will drive the demand from both the developing and the developed world for influenza vaccines. The emerging markets will benefit from improved healthcare systems and in turn they will add to the demand of the influenza vaccines owing to their high birth rates. Furthermore, research and development will lead to continuous innovation within the vaccines industry. Advancements will be made in the delivery and target technology used in the influenza vaccines.

The lead analyst of the report commented "The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market. There is an increasing focus to identify the research gaps and unmet needs of the influenza vaccines market. This includes vaccine technology that provides wider coverage and easier access and administration of the influenza vaccines. This breeds a strong platform for both start-ups and larger pharmaceutical companies to create newer influenza vaccine technology that is not already on the market. This prevents stagnation within the market and will help drive the growth of the influenza vaccines market."

Leading companies featured in the report include Sanofi Pasteur, Seqirus, GlaxoSmithKline (GSK), AstraZeneca, Abbott Laboratories, Sinovac Biotech and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever